Table 1.
Donors included in the study.
All donors | cHCV | SVR | HD |
---|---|---|---|
n=29 | n=37 | n=25 | |
Male, n (%) | 16 (55) | 21 (57) | 12 (48) |
Age, years, median (IQR1-3) | 48 (42-55) | 48 (44-58) | 38 (31-46) |
IgG anti-CMV positive, n (%) | 14 (48) | 24 (51) | 11 (44) |
Cirrhosis, n (%) | 5 (17) | 8 (22) | na |
Treatment experienced, n (%) | 18 (62) | 37 (100) | na |
Treatment (n per type: 0/1/2/3) | 11/12/6/0 | 0/26/10/1 | na |
Delay post-treatment, years, median (IQR1-3) | 3.8 (3.4-4.2) | 1.7 (0.9-3.2) | na |